AZL

0.00%

1.6¢ arizona lithium limited

Good input mate but i refresh my commsec account way more then...

First 3 Last

Share
Profile

Follow
Littlefish88

527 Posts.

77

06/12/21

15:54

Post #: 58104263
Share

Originally posted by bluebaggas: ↑

I think we all need to relax. All 32 lithium stocks on my watch list are down today between 2 and 20%.

The story is the same over the last month - the majority of lithium stocks from large to small caps are all down significantly.

The sector has run hot all year. The market has been looking for an excuse to pull back. The pull back has been largely driven by macro factors that have nothing to do with the Big Sandy project.

Negative sentiment around BLM approval should be offset by positive sentiment around the metallurgical results and a growing awareness that from a valuation perspective the most important thing is that we produce a scoping study (then PFS, DFS). BLM drilling approval coming through this year or early next year won't make a difference to when these studies can be produced. The bulk sample is the main thing that AZL would need to feed in to the scoping study (not the extra 145 holes).

AZL could produce a scoping study based on the current resource and it would likely have a NPV around the billion dollar mark. Resource upgrades would then be incorporated in to an updated PFS or DFS down the track.

Personally, the key milestones I'm looking for over the next 6-12 months are:
- Appointment of a group to perform the initial scoping study
- Finalisation of preliminary flow sheet
- Commencement of scoping study
- Construction of pilot plant
- BLM drilling approval
- Bulk sample taken from Big Sandy
- Commissioning of pilot plant
- Release of scoping study

If AZL can get to that point I think fair value would be around $400m MC. $600m MC on PFS and $800m-1b MC on DFS (assuming some binding off takes have been signed).

Of course BLM drilling approval is important and will impact sentiment, but there are more important milestones in the short term.

Obviously to realise any value from Big Sandy, AZL will need some sort of mining permit. Some of the challenges raised and addressed in the drilling permitting process will likely be similar to those in the mining permitting process, so from that perspective having a positive result in the drilling permit process is key. But whether that approval comes this year or early next year doesn't really matter IMO.

Sit back, relax, stop refreshing your CommSec account 10 times per hour, and enjoy the ride over the next 12 to 36 months.

Expand

Good input mate but i refresh my commsec account way more then that, i think i have a problem. Im just praying that AZl will be more then 15cents in November as i have a lot of options i don't want to waste.

AZL Price at posting: 7.8¢ Sentiment: Hold Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BUX

Buxton projects new graphite province discovery at WA Narryer play

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 108 more messages in this thread...

First 3 Last

Add AZL (ASX) to my watchlist

(20min delay)
Last 1.6¢		Change 0.000(0.00%)		Mkt cap ! $71.58M

Open	High	Low	Value	Volume
1.6¢	1.6¢	1.6¢	$8.871K	555.5K

Buyers (Bids)

No.	Vol.	Price($)
45	12597869	1.5¢

Sellers (Offers)

Price($)	Vol.	No.
1.6¢	526376	4

View Market Depth

No.	Vol.	Price($)
44	12544869	0.015
58	15213529	0.014
17	4046915	0.013
10	4258696	0.012
8	4552000	0.011

Price($)	Vol.	No.
0.016	526376	4
0.017	4287901	18
0.018	3376831	13
0.019	3104989	10
0.020	1814125	10

Last trade - 16.10pm 04/10/2024 (20 minute delay)

AZL (ASX) Chart

Good input mate but i refresh my commsec account way more then...

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Good input mate but i refresh my commsec account way more then...

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News